16 November 2026 | Monday | News
Image Source: Public Domain
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®” (generic name: lecanemab) has been launched in Japan.
LEQEMBI Pen was approved as a new route of administration in Japan on September 16, 2026, and was published in Japan’s National Health Insurance (NHI) Drug Price List today. Following the United States, Japan is the second country where LEQEMBI’s subcutaneous formulation has been launched.
LEQEMBI Pen is an autoinjector formulation that enables either patient self-administration, or administration by a care partner, using two pens (500 mg total) once weekly. With this launch, LEQEMBI treatment now offers a new option of once-weekly SC administration, in addition to intravenous (IV) administration every two weeks in a medical facility.
LEQEMBI Pen may reduce the time required for anti-amyloid therapy administration compared with IV infusions (approximate injection time of 15 seconds per injection). In addition to administration at a medical facility, the possibility of self-administration at home or while traveling may reduce the burden of clinic visits for patients and their care partners and provide greater flexibility in treatment, allowing patients to make treatment choices that better fit their lifestyles, including fewer constraints on going out and traveling. These features are expected to lower barriers to initiating and continuing treatment with LEQEMBI. LEQEMBI Pen also may reduce healthcare resources associated with IV administration, such as nurse monitoring and infusion capacity, contributing to a more streamlined Alzheimer’s disease (AD) treatment pathway. For amyloid-related imaging abnormalities (ARIA) monitoring, as with IV administration, brain magnetic resonance imaging (MRI) is performed prior to initiating treatment and at specified time points after treatment initiation.
The following points are stipulated to be observed when self-administering.
AD is a progressive, relentless disease with Aβ and tau as hallmarks that is caused by a continuous underlying neurotoxic process driven by protofibrils that begins before amyloid plaque accumulation and continues after plaque removal.1,2,3 Only LEQEMBI fights AD in two ways – targeting both protofibrils and amyloid plaque.
Eisai serves as the lead for lecanemab’s development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
© 2026 Biopharma Boardroom. All Rights Reserved.